Careers

Actinium Pharmaceuticals, Inc. is focused on developing therapies for the treatment of cancer patients with unmet needs with the goal of improving patients’ outcomes. If you share in this vision and are interested in joining the Actinium team please feel free to submit your resume by email to careers@actiniumpharma.com.

Openings

We currently do not have any openings.

Actinium Pharmaceuticals, Inc. is aware of employment scams which make false use of the Actinium company logo, emails and staff names to defraud job seekers. Actinium will never ask for money or sensitive personal information, such as bank account details, during the recruitment process. Please be aware that if you are approached with such a request on behalf of Actinium, do not provide any personal information or pay any fees as the recruitment may be fraudulent. All legitimate company emails come from @actiniumpharma.com. Actinium accepts no responsibility for any costs or charges incurred as a result of fraudulent activity.

Bone Marrow Transplant Induction and Conditioning in One

Iomab-B, Actinium’s lead asset, is being studied in the pivotal Phase 3 SIERRA clinical trial as an induction and conditioning agent in patients over the age of 55 with active relapsed or refractory Acute Myeloid Leukemia (AML) prior to receiving a bone marrow transplant (BMT), also known as a hematopoietic stem cell transplant or HSCT.

View Clinical Panel Discussion

Robust Pipeline

Actinium Pharmaceuticals' drug development pipeline features Iomab-B with positive pivotal Phase 3 results, Iomab-ACT, which is intended to be a conditioning regimen for cell and gene therapies and Actimab-A, which is being studied in combination with other regimens in AML to leverage its mutation-agnostic, resistant mechanism of action in collaboration under the NCI CRADA for late-stage development. Actinium is focused on continuing to expand its drug development pipeline of targeted radiotherapies for patients with blood cancers and solid tumors.

View Pipeline

Careers

Openings

Bone Marrow Transplant Induction and Conditioning in One

Robust Pipeline

Email Sign Up